Valante confirms acquisition of female Viagra manufacturer sprout
-
Last Update: 2015-08-21
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Valeant pharmaceuticals International (NYSE: VRx) confirmed that the company will acquire sprout pharmaceuticals with about $1 billion in cash, and the transaction is expected to be completed in the third quarter of this year According to the agreement, valante will pay US $500 million in cash after the completion of the transaction, and another US $500 million in the first quarter of next year Meanwhile, sprout will also get part of the profits of the drug in the future commercialization process Sprout is the manufacturer of addyi, the first female aphrodisiac, and has just been approved by the U.S Food and drug administration So far this year, valante's shares have risen 92%, while the S & P 500 has risen just 1%.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.